Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia.
Pyzer AR, Dillon LW, Sharon E, Karrison TG, Zha Y, Fulton N, Gui G, Andrew G, Streicher H, Sweet K, Yaghmour G, Liu JJ, Jonas BA, Schimmer AD, Grant S, Zeidan AM, Hildebrandt GC, Lowrey CH, Mattison RJ, Palmisiano N, Salhotra A, Tzachanis D, Baer MR, Lin TL, Patel P, Chen H, Stadler WM, Odenike O, Larson RA, Gajewski TF, Hourigan CS, Stock W, Liu H.
Pyzer AR, et al. Among authors: liu jj.
Blood Adv. 2025 May 13;9(9):2144-2152. doi: 10.1182/bloodadvances.2024015176.
Blood Adv. 2025.
PMID: 39928953
Free PMC article.
Clinical Trial.